AKTX

Akari Therapeutics Plc ADR

Sep 16 • 04:00PM ET

0.7550

-0.0205 -2.64 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY NBIX ARGX ADAP FATE CLLS TGTX MCRB VCNX

Index	-	P/E	-	EPS (ttm)	-0.39	Insider Own	0.40%	Shs Outstand	32.61M	Perf Week	-10.13%
Market Cap	24.62M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	66.60%	Shs Float	32.48M	Perf Month	-25.24%
Enterprise Value	23.40M	PEG	-	EPS next Q	-0.09	Inst Own	1.72%	Short Float	0.08%	Perf Quarter	-30.73%
Income	-12.29M	P/S	-	EPS this Y	68.44%	Inst Trans	79.53%	Short Ratio	0.50	Perf Half Y	-31.36%
Sales	0.00M	P/B	0.96	EPS next Y	-3.37%	ROA	-43.90%	Short Interest	0.02M	Perf YTD	-38.11%
Book/sh	0.79	P/C	8.89	EPS next 5Y	26.49%	ROE	-112.22%	52W High	3.85 -80.39%	Perf Year	-77.12%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	- -	ROIC	-48.00%	52W Low	0.57 32.13%	Perf 3Y	-96.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.01% 8.65%	Perf 5Y	-97.63%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.28%	Oper. Margin	-	ATR (14)	0.06	Perf 10Y	-99.39%
Dividend Ex-Date	-	Quick Ratio	0.19	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.19	EPS Q/Q	92.41%	SMA20	-7.92%	Beta	0.30	Target Price	4.53
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-22.01%	Rel Volume	0.88	Prev Close	0.78
Employees	9	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	-33.39%	Avg Volume	49.20K	Price	0.75
IPO	May 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	43,417	Change	-2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-25	Initiated	Maxim Group	Buy	$5
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Sep-05-25 06:45AM	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +12.15%
Sep-03-25 08:30AM	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -6.42%
Aug-14-25 09:15AM	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Jul-29-25 09:15AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Jul-23-25 08:55AM	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers (GlobeNewswire)
08:45AM	Loading…
Jul-22-25 08:45AM	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-25-25 09:00AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent (GlobeNewswire)
Jun-18-25 08:50AM	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India (GlobeNewswire)
May-29-25 09:15AM	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology (GlobeNewswire)
May-22-25 09:00AM	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire)
May-15-25 08:05AM	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 08:45AM	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology (GlobeNewswire)
Apr-22-25 09:05AM	Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala (GlobeNewswire) +6.25%
08:00AM	Loading…
Apr-16-25 08:00AM	Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.24%
Mar-20-25 08:44AM	Akari Therapeutics appoints Abizer Gaslightwala as CEO (SeekingAlpha) +20.00%
08:35AM	Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer (GlobeNewswire)
Mar-03-25 09:00AM	Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules (GlobeNewswire) +7.70%
Feb-19-25 09:00AM	Akari Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire) +5.30%
Feb-03-25 08:00AM	Akari Therapeutics Joins Webull Corporate Connect Service Platform (GlobeNewswire) +9.17%
Dec-18-24 08:51AM	Akari Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-16-24 09:05AM	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer (GlobeNewswire)
Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
08:00AM	Loading…
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)
Jul-05-23 08:00AM	Akari Therapeutics Appoints Industry Veteran Wael Hashad to Board of Directors (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire) +12.28%
08:00AM	Akari Therapeutics to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-01-23 08:00AM	Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights (GlobeNewswire)
Apr-25-23 04:15PM	Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement (GlobeNewswire) +6.31%
Apr-19-23 02:01PM	Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m (Simply Wall St.)
Apr-14-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs (GlobeNewswire) +5.26%
Apr-11-23 08:00AM	Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-03-23 08:00AM	Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting (GlobeNewswire) +12.00%
Mar-30-23 09:09AM	Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering (GlobeNewswire) -16.34%
Mar-29-23 08:00AM	Poland and U.K. Regulatory Authorities URPL and MHRA Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study (GlobeNewswire) -5.23%
Feb-21-23 08:00AM	Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings (GlobeNewswire) -10.88%
Feb-15-23 08:00AM	Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) (GlobeNewswire)
Feb-13-23 08:00AM	Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults (GlobeNewswire)
Jan-04-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2023 (GlobeNewswire) +5.09%
Dec-01-22 08:00AM	Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference (GlobeNewswire)
Nov-22-22 08:00AM	Akari Therapeutics to Participate in the Ophthalmology Day at BTIG (GlobeNewswire)
Nov-10-22 08:00AM	Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA (GlobeNewswire) +5.88%
Nov-09-22 08:00AM	Akari Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +8.51%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
08:00AM	Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer (GlobeNewswire)
Oct-31-22 08:00AM	Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference (GlobeNewswire)
Oct-28-22 04:30PM	Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Sep-27-22 08:00AM	Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Sep-22-22 08:00AM	Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-12-22 08:00AM	Akari Therapeutics Announces $12.75 Million Registered Direct Offering (GlobeNewswire) -27.88%
Sep-08-22 06:48AM	One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year (Simply Wall St.) -9.01%
Aug-01-22 08:00AM	Akari Therapeutics Narrows Pipeline Focus (GlobeNewswire) +5.26%
Jul-29-22 09:36AM	Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? (Simply Wall St.) +15.42%
Jul-28-22 08:00AM	Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy (GlobeNewswire)
Jul-20-22 06:00AM	Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Jul-07-22 08:00AM	Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) (GlobeNewswire) +9.47%
Jun-13-22 07:00AM	Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies (GlobeNewswire)
May-19-22 04:05PM	Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -7.63%
May-16-22 06:00AM	Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress (GlobeNewswire)
May-11-22 07:00AM	Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -5.04%
May-10-22 07:00AM	Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology (GlobeNewswire) +5.31%
May-09-22 07:00AM	Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) (GlobeNewswire)
Mar-21-22 08:00AM	Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting (GlobeNewswire)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaslightwala Abizer	CEO	Aug 21 '25	Buy	0.94	10,000	9,400	287,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 22 '25	Buy	0.93	8,000	7,440	295,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 25 '25	Buy	0.90	3,000	2,700	298,574	Aug 29 04:55 PM
Gaslightwala Abizer	President & CEO	Jun 24 '25	Buy	1.16	5,203	6,035	277,574	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 23 '25	Buy	1.15	943	1,084	272,371	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 20 '25	Buy	1.20	10,000	12,000	271,428	Jun 24 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 17 '25	Buy	1.20	15,000	18,000	261,428	Jun 20 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your FINVIZ experience